Skip to content
Supplementary Figure 1 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors — J. Andrew Livingston (2025) | RDL Network